search results for: Semaglutide

ARCH-backed start­up Met­sera launch­es with $290M to take on obe­si­ty gi­ants

Yesterday
Financing

Lil­ly plans for Zep­bound la­bel ex­pan­sion in­to sleep ap­nea in mid-2024 on back of Phase 3 win

2 days ago
R&D

Ver­tex's $4.9B bet; Lay­offs at No­var­tis, Genen­tech, Sanofi; Star founders un­veil new star­tups; and more

6 days ago
Weekly

EMA probe finds no causal link be­tween semaglu­tide and sui­ci­dal thoughts, self-harm

Last week
Pharma
FDA+

Eli Lil­ly los­es case against Flori­da com­pound­ing phar­ma­cy

Last week
Pharma
Law

Gink­go, No­vo Nordisk forge ‘flex­i­ble’ re­search pact, from dis­cov­ery to man­u­fac­tur­ing

Last week
Deals
Manufacturing

No­vo fur­ther boosts ev­i­dence for semaglu­tide’s heart ben­e­fits be­yond weight loss: #ACC24

Last week
R&D

Aca­d­e­m­ic tri­al sug­gests mod­est GLP-1 ef­fect in Parkin­son's dis­ease, but ques­tions re­main

3 weeks ago
R&D

Mar­ket­ingRx roundup: Pfiz­er switch­es up ad­ver­tis­ing du­ties; No­vo Nordisk’s Ozem­pic gets spoofed on SNL

3 weeks ago
Pharma
Marketing

Bernie Sanders im­plores No­vo to cut list prices of Ozem­pic, We­govy

4 weeks ago
Pharma
FDA+

Novo's week­ly in­sulin se­cures CHMP thumbs-up as FDA de­ci­sion looms

4 weeks ago
Pharma

FDA ap­proves Madri­gal’s NASH drug, mark­ing the first-ever treat­ment for the liv­er dis­ease

Last month
Pharma
FDA+

Madri­gal to grap­ple with lack of aware­ness about NASH ahead of po­ten­tial FDA ap­proval

Last month
Pharma
Marketing

The R&D 15: Top phar­ma play­ers shell out record $153B for re­search, and M&A is a prime fo­cus for all

Last month
Bioregnum
R&D

Amy­lyx’s ALS dis­ap­point­ment; Lil­ly's Alzheimer's de­lay; Bay­er stays put; No­vo Nordisk's GLP-1 streak; and more

Last month
Weekly

Akero ex­ec­u­tives point to ad­vanced fi­bro­sis pa­tients for MASH drug

Last month
R&D
Pharma

Up­dat­ed: FDA ap­proves weight loss drug We­govy to re­duce car­dio­vas­cu­lar events

Last month
Pharma
FDA+

No­vo un­like­ly to out­source API pro­duc­tion for GLP-1s but will stay en­gaged with fill-fin­ish part­ners

Last month
Manufacturing
1234 Next page Last page

latest

Most read

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

11 hours ago
Peer Review

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

4 hours ago
Pharma
FDA+

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

4 hours ago
Pharma
Marketing

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

5 hours ago
Pharma

Califf talks bol­ster­ing do­mes­tic drug man­u­fac­tur­ing, for­eign in­spec­tions at House hear­ing

5 hours ago
Pharma
FDA+
see latest stream
A service from the Financial Times